Replies to post #125688 on Biotech Values

[NP1986]

Why are they comparing it against DTIC/TMZ when TMZ isn't even approved for this indication?

Until recently, there weren't many approved treatment options for melanoma. Pfizer's phase III tremelimumab trial used the investigator's choice of DTIC or TMZ as the comparator. I don't see much wrong with using TMZ as a comparator.

Nevertheless, I can't really comment on Allovectin-7 itself.

[drbio45]

thank you

Someone asked me about it and you have given me a very thoughtful response.